Erik A Bey

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. pmc An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone
    Erik A Bey
    Department of Pharmacology, Laboratory of Molecular Stress Responses, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 104:11832-7. 2007
  2. ncbi request reprint Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation
    Heon Joo Park
    Radiobiology Laboratory, Department of Therapeutic Radiology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Int J Radiat Oncol Biol Phys 61:212-9. 2005
  3. ncbi request reprint Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1
    Matthew Ough
    Department of Surgery, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Cancer Biol Ther 4:95-102. 2005
  4. ncbi request reprint Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair
    Melissa S Bentle
    Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Biol Chem 281:33684-96. 2006
  5. pmc Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells
    Elvin Blanco
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, United States
    J Control Release 122:365-74. 2007
  6. pmc Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation
    Ying Dong
    Departments of Pharmacology, Radiation Oncology, Pathology, Biostatistics and Clinical Sciences, and Urology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8807, USA
    Cancer Res 70:8088-96. 2010
  7. doi request reprint An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis
    Xiumei Huang
    Department of Pharmacology, UT Southwestern Medical Center, Dallas, Texas 75390, USA
    Cancer Res 72:3038-47. 2012
  8. ncbi request reprint Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone
    Melissa S Bentle
    Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA
    Cancer Res 67:6936-45. 2007
  9. doi request reprint Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy
    Long Shan Li
    Department of Pharmacology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Texas 75390, USA
    Clin Cancer Res 17:275-85. 2011
  10. pmc Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy
    Ying Dong
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Clin Cancer Res 15:131-9. 2009

Collaborators

  • Jinming Gao
  • John Minna
  • Jieru Meng
  • Ying Dong
  • Haijun Yu
  • Carlton C Barnett
  • A F Gazdar
  • C W Song
  • David A Boothman
  • Melissa S Bentle
  • Kathryn E Reinicke
  • Long Shan Li
  • William G Bornmann
  • Julio Morales
  • Malina Patel
  • Gang Huang
  • Xiumei Huang
  • Chalermchai Khemtong
  • Georgia Konstantinidou
  • Elvin Blanco
  • Heon Joo Park
  • Matthew Ough
  • Farjana J Fattah
  • Longshan Li
  • Xiuquan Luo
  • Zachary Moore
  • Huabing Chen
  • Noelle S Williams
  • Joseph S Bair
  • Paul J Hergenrother
  • Yiguang Wang
  • Elizabeth I Parkinson
  • Jessica A Kilgore
  • Rolf A Brekken
  • Biswanath Patra
  • Jingsheng Yan
  • Xian Jin Xie
  • Katja Schuster
  • Pier Paolo Scaglioni
  • Andrea Rabellino
  • Su Geun Yang
  • Jimin Ren
  • Michael S Maira
  • A Dean Sherry
  • Augusto Amici
  • Jagadeesh Setti Guthi
  • Chase W Kessinger
  • Brent D Weinberg
  • Damon M Sutton
  • Douglas R Spitz
  • John J Pink
  • Eunkyung Choi
  • Anne Lewis
  • Gerardo Burton
  • Larry W Oberley
  • William Bornmann
  • Gisela M Arzac
  • Robert Griffin
  • Damon Sutton
  • Eun Jung Kim
  • Brent Williams
  • Joseph J Cullen
  • Heon Jin Park
  • Ki Jung Ahn
  • Stephen T Ingalls
  • Justine M Ritchie
  • Rosana I Misico
  • Seung Do Ahn
  • Charles L Hoppel
  • Sang Wook Lee

Detail Information

Publications17

  1. pmc An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone
    Erik A Bey
    Department of Pharmacology, Laboratory of Molecular Stress Responses, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 104:11832-7. 2007
    ..beta-Lapachone killed cells in a tumorselective manner and is indicated for use against NQO1+ NSCLC cancers...
  2. ncbi request reprint Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation
    Heon Joo Park
    Radiobiology Laboratory, Department of Therapeutic Radiology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Int J Radiat Oncol Biol Phys 61:212-9. 2005
    ..To reveal the interaction between beta-lapachone (beta-lap) and ionizing radiation (IR) in causing clonogenic death in cancer cells and to elucidate the potential usefulness of beta-lap treatment in combination with radiotherapy of cancer...
  3. ncbi request reprint Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1
    Matthew Ough
    Department of Surgery, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Cancer Biol Ther 4:95-102. 2005
    ....
  4. ncbi request reprint Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair
    Melissa S Bentle
    Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Biol Chem 281:33684-96. 2006
    ..Thus, Ca(2+) appears to be an important co-factor in PARP-1 hyperactivation after ROS-induced DNA damage, which alters cellular metabolism and DNA repair...
  5. pmc Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells
    Elvin Blanco
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, United States
    J Control Release 122:365-74. 2007
    ..In summary, these data demonstrate the potential of beta-lap micelles as an effective therapeutic strategy against NQO1-overexpressing tumor cells...
  6. pmc Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation
    Ying Dong
    Departments of Pharmacology, Radiation Oncology, Pathology, Biostatistics and Clinical Sciences, and Urology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8807, USA
    Cancer Res 70:8088-96. 2010
    ..Our findings offer a rationale for the clinical utilization of β-lap (Arq 501) as a radiosensitizer in prostate cancers that overexpress NQO1, offering a potentially synergistic targeting strategy to exploit PARP-1 hyperactivation...
  7. doi request reprint An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis
    Xiumei Huang
    Department of Pharmacology, UT Southwestern Medical Center, Dallas, Texas 75390, USA
    Cancer Res 72:3038-47. 2012
    ..Our findings offer preclinical proof-of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum of therapeutically challenging solid tumors, such as pancreatic and lung cancers...
  8. ncbi request reprint Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone
    Melissa S Bentle
    Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA
    Cancer Res 67:6936-45. 2007
    ....
  9. doi request reprint Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy
    Long Shan Li
    Department of Pharmacology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Texas 75390, USA
    Clin Cancer Res 17:275-85. 2011
    ..Although prior work suggested that β-lapachone (β-lap) could be used for the treatment of pancreatic cancers, the lack of knowledge of the compound's mechanism of action prevented optimal use of this agent...
  10. pmc Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy
    Ying Dong
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Clin Cancer Res 15:131-9. 2009
    ....
  11. ncbi request reprint Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses
    Erik A Bey
    Laboratory of Molecular Stress Responses, Department of Pharmacology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Cell Physiol 209:604-10. 2006
    ..We have learned these lessons and now adopted strategies to exploit them for improved therapy. These examples will be discussed and compared to the pioneering findings of researchers in the Pardee laboratory over the years...
  12. pmc Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy
    Gang Huang
    Departments of Pharmacology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 8807, USA
    Theranostics 3:116-26. 2013
    ....
  13. pmc Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations
    Georgia Konstantinidou
    Division of Hematology and Oncology, Simmons Comprehensive Cancer Center, and Hamon Center for Therapeutic Oncology Research, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas TX 75390, USA
    Cancer Res 69:7644-52. 2009
    ..These findings may have general applicability in cancer therapy, because aberrant activation of PI3K occurs frequently in human cancer...
  14. ncbi request reprint New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors
    Melissa S Bentle
    Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106, USA
    J Mol Histol 37:203-18. 2006
    ..In particular, we focus on a novel anti-tumor agent, beta-lapachone, and its potential to block transformation by modulating poly(ADP-ribose) polymerase-1...
  15. pmc In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles
    Chalermchai Khemtong
    Department of Pharmacology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 35790, USA
    Cancer Res 69:1651-8. 2009
    ..This combination of ORS imaging with a tumor vasculature-targeted, ultrasensitive SPPM design offers new opportunities in molecular imaging of cancer...
  16. ncbi request reprint Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases
    Julio Morales
    Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75399
    Crit Rev Eukaryot Gene Expr 24:15-28. 2014
    ..The PARP pathway and its inhibition thus offers a number of opportunities for therapeutic intervention in both cancer and other disease states. ..
  17. ncbi request reprint Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels
    Kathryn E Reinicke
    Laboratory of Molecular Stress Responses, Case Western Reserve University, Cleveland, OH 44106, USA
    Clin Cancer Res 11:3055-64. 2005
    ..e., in the acidic local environment of the tumor tissue), should reduce normal tissue toxicity while eliciting tumor-selective cell killing by NQO1 bioactivation...